Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PTP4A3 | O75365 | 1/20 | 0.33 |
| ▸ | PTP4A2 | Q12974 | 1/20 | 0.33 |
| ▸ | PTP4A1 | Q93096 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 5/20 | 0.31 |
| ▸ | CA1 | P00915 | 5/20 | 0.31 |
| ▸ | CA2 | P00918 | 5/20 | 0.31 |
| ▸ | CA9 | Q16790 | 5/20 | 0.31 |
| ▸ | CA7 | P43166 | 4/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL666918 | 1.00 | TSHR (0.50) | TSHRHCAR2ADRA1APDE4DGAA | |
| SCHEMBL1532594 | 1.00 | TSHR (0.50) | TSHRHCAR2ADRA1APDE4DGAA | |
| SCHEMBL3338061 | 0.97 | TSHR (0.48) | TSHRHCAR2ADRA1APDE4DGAA | |
| SCHEMBL448478 | 0.97 | TSHR (0.48) | TSHRHCAR2ADRA1APDE4DGAA | |
| SCHEMBL10948804 | 0.84 | TSHR (0.38) | TSHRHCAR2MAPT | |
| SCHEMBL2598286 | 0.82 | TSHR (0.48) | TSHRHCAR2ADRA1APDE4DGAA | |
| SCHEMBL10687993 | 0.82 | TSHR (0.48) | TSHRHCAR2ADRA1APDE4DGAA | |
| SCHEMBL17472929 | 0.82 | TSHR (0.36) | TSHR | |
| SCHEMBL173350 | 0.82 | TSHR (0.36) | TSHR | |
| SCHEMBL173352 | 0.82 | TSHR (0.36) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114930630-A | Inorganic coating crosslinked separator | 旭化成株式会社 | 2022-08-19 | — | — | CN | disclosed |
| CN-114342145-A | Nonaqueous secondary battery and nonaqueous electrolyte | 旭化成株式会社 | 2022-04-12 | — | — | CN | disclosed |
| CN-114287077-A | Nonaqueous electrolyte solution, battery pack, and method for producing battery pack | 旭化成株式会社 | 2022-04-05 | — | — | CN | disclosed |
| CN-114223094-A | Composite single-layer chemically cross-linked separator | 旭化成株式会社 | 2022-03-22 | — | — | CN | disclosed |
| CN-114175385-A | Composite laminated chemically cross-linked separator | 旭化成株式会社 | 2022-03-11 | — | — | CN | disclosed |
| WO-2020144873-A1 | OFF-FLAVOR INHIBITOR | 長岡香料株式会社 | 2020-07-16 | — | — | WO | disclosed |
| US-20180332878-A1 | BITTER TASTE INHIBITOR | NAGAOKA CO., LTD. (JP) | 2018-11-22 | — | — | US | disclosed |
| US-20180332879-A1 | AGENT FOR IMPROVING AFTERTASTE HAVING HIGH INTENSITY SWEETENERS | NAGAOKA CO., LTD. (JP) | 2018-11-22 | — | — | US | disclosed |
| US-9404131-B2 | Process for the preparation of ingenol-3-angelate | LEO LABORATORIES LIMITED (IE) | 2016-08-02 | — | — | US | disclosed |
| US-20150024443-A1 | PROCESS FOR THE PREPARATION OF INGENOL-3-ANGELATE | LEO LABORATORIES LIMITED (IE) | 2015-01-22 | — | — | US | disclosed |
| US-20090325971-A1 | Pentacyclic Alkaloid Compounds and Methods of Use Thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325971-A1 | Pentacyclic Alkaloid Compounds and Methods of Use Thereof | CIAPIN1, CCR5, CPB1 | TSHR 3651/4885HCAR2 835/4885ADRA1A 4129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.